- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02386319
Anxiolytic and Analgesic Effects of Melatonin (ANAN-Melatonin)
Anxiolytic and Analgesic Effects of Melatonin: A Randomized, Double-blinded, Placebo-controlled Clinical Study
Study Overview
Detailed Description
The study is separated into two parts. In the first part the patients are undergoing cosmetic breast surgery, and in the second part the patient undergo inguinal og umbilical surgery.
The first part is a cohort at 12 patients undergoing breast surgery. All patients in this group will be treated with melatonin, and the investigators intend to investigate the pharmacokinetic parameters of melatonin. Melatonin will be administrated 60 min. before surgery and the evening after surgery at 9 pm.
All patients will receive an intravenous catheter. The intravenous catheter will be used for blood sampling. A baseline blood sample will be taken 65 min before surgery (baseline) and thereafter blood samples will be obtained 0 min., 15 min., 30 min., 45 min., 60 min., 90 min., 120 min., 180 min., 240 min., 300 min., 360 min. and 420 min. after administration of melatonin. Blood samples will be obtained again after administration of melatonin at 9 pm. in the evening in the same manner as described above. Plasma samples will be stored at minus 80 C and analyzed at the research laboratory of the Department of surgery, Herlev Hospital. The analysis will be preformed with the RIA-technique.
The second part is a randomized, double-blind, placebo-controlled study with a total of 32 participants divided into a intervention group (16) and a placebo group (16). In this part the investigators intend to investigate the anxiolytic and sleep-promoting effects of melatonin. Melatonin and placebo will be administrated at 9 pm. the evening before surgery, 120 min. before surgery, immediately after surgery in the PACU and at 9 pm the evening after surgery.
Anxiety will be measured by the State-Trait Anxiety Inventory (STAI) and a VAS-scale (0 mm = no anxiety and 100 mm = worst anxiety). Quality of sleep will be measured at the VAS-scale as well (0 mm = best sleep and 100 = worst sleep).
Randomization will be performed by a computer at randomization.com. The "first generator" function is used. The randomization will be preformed in blocks of 4 patients in each.
Manufacturing of medications and randomization will be made by an independent pharmacist.
The primary outcome is preoperative anxiety as measured on the STAI. A previous study investigated preoperative anxiety before hernia surgery and found a mean of 35.4 (SD 10.0) on the STAI scale. There does not exist any generally accepted measure of how large a change on the STAI scale constitutes a clinically important difference. However, a change equal to one standard deviation has been suggested. In the present study, this corresponds to a minimal relevant difference (MIREDIF) of 10 points on the STAI scale or 28%. A power of 80% was defined, a significance level of 5% and a minimal relevant difference (MIREDIF) of 28%. From these assumptions, 16 patients in each treatment group is needed
Statistics Anxiety and sleep quality will be compared at individual timepoints between groups Comparison will be performed either by Mann-whitheys-test or unpaired t-test, depending on the distribution of data. Values are considered significant at a p-value at 5% or less. Data will be reported as mean (SD) or median (IQR) depending on the distribution of data.
Data for the blood samples will be presented as AUC plasma concentrations, half-life, maximum concentration and time to maximum concentration.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Herlev, Denmark, 2730
- Herlev Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria part one:
- Patients who are candidates for breast surgery.
- BMI between 18 and 30
- Visible veins in the elbow region
- Fertile women use anti-contraception and have performed a negative pregnancy test
Exclusion Criteria part one:
- Patients, who use daily opioids, benzodiazepines or melatonin
- Patients diagnosed with a psychiatric disorder (defined as in medical treatment)
- Patients with severe physical disease (ASA 3-4)
- Patients with previous or ongoing alcohol or drug abuse
- Patients with liver disease (defined as in medical treatment)
- Patients diagnosed sleep disturbances
- Patients who are unable to cooperate according to the protocol
- Patients with allergy to melatonin
Inclusion Criteria part two:
- Male patients who are candidates for inguinal or umbilical hernia reapir
Exclusion Criteria part two:
- Patients, who use daily opioids, benzodiazepines or melatonin
- Patients diagnosed with a psychiatric disorder (defined as in medical treatment)
- Patients with severe physical disease (ASA 3-4)
- Patients with previous or ongoing alcohol or drug abuse
- Patients with liver disease (defined as in medical treatment)
- Patients diagnosed sleep disturbances
- Patients who are unable to cooperate according to the protocol
- Patients with allergy to melatonin
Withdrawal- and drop-out criteria part 2:
- Patients can withdraw at any time during trial
Complications during surgery occur that lead to:
- Immediate reoperation
- Hospitalization to intensive care unit
- If it is considered in the best interest of the patients physical- and psychological health to withdraw from the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Melatonin
Melatonin 10 mg, gelatin capsules. Pharmacokinetic study: 10 mg x 2. In the morning before surgery and in the evening after surgery. Anxiolytic and analgesic study: 10 mg x 4. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery. |
Gelatin capsules
|
Placebo Comparator: Placebo
Gelatin capsules.
Anxiolytic and analgesic study.
Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.
|
Placebo capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Preoperative Anxiety
Time Frame: 60 minutes preoperative
|
The "State" scale of the State-Trait Anxiety Inventory (STAI).
Construct: Current level of anxiety.
Scale range: 20-40 (higher scores indicate higher level of current anxiety) Scores are calculated according to the STAI scoring manual by adding point from each item (possible point for each item is 1-4).
|
60 minutes preoperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postoperative Anxiety
Time Frame: at the preoperative interview, 60 minutes prior to surgery and 4 hours postoperatively.
|
State-Trait Anxiety Index
|
at the preoperative interview, 60 minutes prior to surgery and 4 hours postoperatively.
|
Pre- and Postoperative Anxiety
Time Frame: at the preoperative interview, 60 minutes prior to surgery, 1 and 4 hours postoperatively.
|
Visual analog scale
|
at the preoperative interview, 60 minutes prior to surgery, 1 and 4 hours postoperatively.
|
Intraoperative Requirement of Remifentanil
Time Frame: intraopeative
|
µg/kg/min
|
intraopeative
|
Intraoperative Requirement of Propofol
Time Frame: intraoperative
|
mg/kg/min
|
intraoperative
|
Use of Rescue-opioids in the PACU
Time Frame: 0-24 hours postoperative
|
dose
|
0-24 hours postoperative
|
Use of Rescue-opioids in the Ward
Time Frame: 0-24 hours postoperative
|
dose
|
0-24 hours postoperative
|
Perioperative Sleep Quality
Time Frame: 24 hours
|
Visual analog scale
|
24 hours
|
General Well-being and Fatigue
Time Frame: 24 hours
|
Visual analog scale
|
24 hours
|
Plasma Concentrations of Melatonin
Time Frame: baseline, 0 min, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 180 min, 240 min, 300 min, 360 min and 420 min. after melatonin administration.
|
pg/ml
|
baseline, 0 min, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 180 min, 240 min, 300 min, 360 min and 420 min. after melatonin administration.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dennis B Zetner, MD., Herlev Hospital, Herlev Ringvej 75, Herlev, Denmark
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Melatonin1234
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiRecruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
Nazife Begüm KARANCompletedDental Anxiety | Sedative; Anxiety DisorderTurkey
-
Loyola UniversityCompletedAnxiety | Anxiety State | Procedural AnxietyUnited States
-
Eli Lilly and CompanyCompletedAnxiety Neuroses | Anxiety States, Neurotic | Neuroses, AnxietyUnited States, Mexico, South Africa
-
West University of TimisoaraUnknownAnxiety Disorder/Anxiety StateRomania
-
Dr. Nazanin AlaviActive, not recruitingGeneralized Anxiety Disorder | AnxietyCanada
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States